Gene Therapy Zynteglo denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for gene therapy zynteglo are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied Zynteglo Under Step Therapy — and Why You Can Appeal

Blue Cross Blue Shield's step-therapy (also called "fail-first") protocols typically require patients to try and fail one or more lower-cost treatments before a higher-cost therapy is authorized. For Zynteglo (betibeglogene spartacus) — a gene therapy for transfusion-dependent beta-thalassemia — a step-therapy denial usually means BCBS believes the patient has not yet tried a required prior therapy, or that the documentation of prior therapy failure was insufficient.

For a condition like transfusion-dependent beta-thalassemia, patients have almost universally been on chronic transfusion therapy for years before gene therapy is considered. The appeal strategy centers on demonstrating — with detailed records — that the step-therapy requirements have in fact already been met.

## Why This Denial Is Appealable

Most states have enacted step-therapy exception laws requiring insurers to grant exceptions when a patient has already tried the required prior therapy or when the required prior therapy is medically inappropriate for the specific patient. At the federal level, ACA §2719 and ERISA §503 guarantee full and fair review. A well-documented record of prior transfusion dependency and previous therapeutic management typically satisfies the step-therapy exception criteria.

## Federal Appeal Framework

• Step-therapy exception request: File this simultaneously with or before the formal appeal. Demonstrate that required prior steps have been completed or are medically inappropriate.
• Internal appeal (Level 1): File under ACA §2719 / ERISA §503 within the deadline stated on the denial letter. Submit a complete prior-treatment history.
• External review: If the internal appeal fails, request IRO review under ACA §2719. The typical window is 4 months from the final adverse benefit determination — verify the exact deadline on your notice.
• Expedited option: If delay would seriously jeopardize health, request expedited review for a 72-hour decision.

## Documentation to Gather

1. Complete prior treatment history: Detailed records of all prior therapies — chronic transfusion therapy, chelation, any pharmacologic management — with start dates, end dates, dosing, and clinical outcomes or reasons for inadequacy. 2. Diagnosis confirmation: Genetic testing and clinical records confirming transfusion-dependent beta-thalassemia. 3. Clinical severity evidence: Chart notes documenting disease progression, iron overload, organ burden, and quality-of-life impact despite prior therapies. 4. Prescriber step-therapy exception letter: A letter from the treating hematologist documenting which prior steps have been completed, why they were inadequate, and why Zynteglo is the appropriate next step per the FDA-approved prescribing label and applicable hematology guidelines. 5. State step-therapy exception law reference: If your state has a step-therapy exception statute, reference it in the appeal letter.

## Criteria-Mapping Structure

Obtain BCBS's step-therapy protocol for Zynteglo from the plan's published medical/coverage policy. Map each required prior step to the patient's actual treatment history:

| Required Prior Therapy Step | Patient History Evidence | |---|---| | [Step 1 as listed in plan policy] | [Dates, duration, dose, and outcome from chart] | | [Step 2 as listed in plan policy] | [Dates, duration, dose, and outcome from chart] | | Medical exception basis (if step not tried) | [Prescriber explanation of medical contraindication or inappropriateness] |

For the exact step-therapy requirements BCBS applies, consult the plan's published coverage policy directly. For the approved indication and prescribing parameters, consult the FDA-approved prescribing label.